These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 24571452

  • 1. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J, Chen Y, Wan J, Liu X, Yu C, Li W.
    Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
    [Abstract] [Full Text] [Related]

  • 2. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
    Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W.
    Br J Cancer; 2013 Jul 23; 109(2):342-50. PubMed ID: 23807172
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
    Kim LH, Shin JA, Jang B, Yang IH, Won DH, Jeong JH, Chung TH, Cho NP, Cho SD.
    Arch Oral Biol; 2017 Jan 23; 73():1-6. PubMed ID: 27632413
    [Abstract] [Full Text] [Related]

  • 4. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC, Baxter RD, Hunt KM, Agarwal J, Elmets CA, Athar M, Afaq F.
    Oncotarget; 2015 Sep 29; 6(29):28296-311. PubMed ID: 26299806
    [Abstract] [Full Text] [Related]

  • 5. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 6. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K, Harada M.
    Oncotarget; 2014 Nov 30; 5(22):11399-412. PubMed ID: 25333266
    [Abstract] [Full Text] [Related]

  • 7. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC.
    PLoS One; 2011 Nov 30; 6(9):e24102. PubMed ID: 21949692
    [Abstract] [Full Text] [Related]

  • 8. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K, Prouzet-Mauléon V, Rousseau B, Pigneux A, Jeanneteau M, Giraudon M, Allou K, Dubus P, Belloc F, Mahon FX.
    Oncotarget; 2016 Jan 05; 7(1):845-59. PubMed ID: 26625317
    [Abstract] [Full Text] [Related]

  • 9. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 05; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Kiprianova I, Remy J, Milosch N, Mohrenz IV, Seifert V, Aigner A, Kögel D.
    Neoplasia; 2015 Jul 05; 17(7):564-73. PubMed ID: 26297434
    [Abstract] [Full Text] [Related]

  • 11. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y, Harashima N, Tajima Y, Harada M.
    Oncotarget; 2015 Dec 08; 6(39):41902-15. PubMed ID: 26506422
    [Abstract] [Full Text] [Related]

  • 12. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.
    Shao H, Jing K, Mahmoud E, Huang H, Fang X, Yu C.
    Mol Cancer Ther; 2013 Dec 08; 12(12):2640-50. PubMed ID: 24126433
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
    Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P.
    J Cell Physiol; 2013 Oct 08; 228(10):1996-2005. PubMed ID: 23674352
    [Abstract] [Full Text] [Related]

  • 14. C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
    Jiang S, Wang Q, Feng M, Li J, Guan Z, An D, Dong M, Peng Y, Kuerban K, Ye L.
    Appl Microbiol Biotechnol; 2017 Feb 08; 101(4):1535-1546. PubMed ID: 27807662
    [Abstract] [Full Text] [Related]

  • 15. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.
    Leukemia; 2013 Aug 08; 27(8):1677-87. PubMed ID: 23360848
    [Abstract] [Full Text] [Related]

  • 16. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
    Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF.
    J Pharmacol Exp Ther; 2012 Jun 08; 341(3):859-72. PubMed ID: 22393246
    [Abstract] [Full Text] [Related]

  • 17. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
    Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G.
    Clin Cancer Res; 2013 Apr 15; 19(8):2117-31. PubMed ID: 23434734
    [Abstract] [Full Text] [Related]

  • 18. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W.
    J Cell Mol Med; 2011 Feb 15; 15(2):316-26. PubMed ID: 20015197
    [Abstract] [Full Text] [Related]

  • 19. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.
    Mol Cancer; 2014 Jan 13; 13():7. PubMed ID: 24418169
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Blood; 2012 Jun 21; 119(25):6089-98. PubMed ID: 22446485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.